Eicosapentaenoic acid in serum phospholipids relates to a less atherogenic lipoprotein profile in subjects with familial hypercholesterolemia

Journal of Nutritional Biochemistry

Volumn 24, Issue 9, 2013, Pages 1604-1608

  Sala Vila, Aleix ^a,b   Cofán, Montserrat ^b   Mateo Gallego, Rocío ^c   Cenarro, Ana ^c   Civeira, Fernando ^c   Ros, Emilio ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Familial hypercholesterolemia; Lipoprotein subfractions; Long chain n 3 polyunsaturated fatty acids

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; DOCOSAHEXAENOIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LEISURE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID BLOOD LEVEL; PHYSICAL ACTIVITY; PROTON NUCLEAR MAGNETIC RESONANCE; QUESTIONNAIRE; SEA FOOD; SMOKING; SPORTING EVENT; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 84881542428     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.01.011     Document Type: Article

References (49)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
2. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982, 23:97-104.
3. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363-1379.
4. Rizzo M., Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 2006, 99:1-14.
5. Adiels M., Olofsson S.O., Taskinen M.R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
6. Krauss R.M. Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 2005, 25:2265-2272.
7. Eslick G.D., Howe P.R.C., Smith C., Priest R., Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009, 136:4-16.
8. De Caterina R. n-3 Fatty acids in cardiovascular disease. N Engl J Med 2011, 364:2439-2450.
9. Satoh N., Shimatsu A., Kotani K., Sakane N., Yamada K., Suganami T., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007, 30:144-146.
10. Maki K.C., Van Elswyk M.E., McCarthy D., Hess S.P., Veith P.E., Bell M., et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr 2005, 24:189-199.
11. Kelley D.S., Siegel D., Vemuri M., Mackey B.E. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 2007, 86:324-333.
12. Neff L.M., Culiner J., Cunningham-Rundles S., Seidman C., Meehan D., Maturi J., et al. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr 2011, 141:207-213.
13. Suzukawa M., Abbey M., Howe P.R., Nestel P.J. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 1995, 36:473-484.
14. Calabresi L., Donati D., Pazzucconi F., Sirtori C.R., Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000, 148:387-396.
15. Mori T.A., Burke V., Puddey I.B., Watts G.F., O'Neal D.N., Best J.D., et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000, 71:1085-1094.
16. Tholstrup T., Hellgren L.I., Petersen M., Basu S., Straarup E.M., Schnohr P., et al. A solid dietary fat containing fish oil redistributes lipoprotein subclasses without increasing oxidative stress in men. J Nutr 2004, 134:1051-1057.
17. Wilkinson P., Leach C., Ah-Sing E.E., Hussain N., Miller G.J., Millward D.J., et al. Influence of α-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 2005, 181:115-124.
18. Nenseter M.S., Rustan A.C., Lund-Katz S., Søyland E., Maelandsmo G., Phillips M.C., et al. Effect of dietary supplementation with n-3 polyunsaturated fatty acids on physical properties and metabolism of low density lipoprotein in humans. Arterioscler Thromb 1992, 12:369-379.
19. Patti L., Maffettone A., Iovine C., Marino L.D., Annuzzi G., Riccardi G., et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 1999, 146:361-367.
20. Rivellese A.A., Maffettone A., Vessby B., Uusitupa M., Hermansen K., Berglund L., et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. Atherosclerosis 2003, 167:149-158.
21. Wooten J.S., Biggerstaff K.D., Ben-Ezra V. Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise. J Appl Physiol 2009, 107:794-800.
22. Li Z., Lamon-Fava S., Otvos J., Lichtenstein A.H., Velez-Carrasco W., McNamara J.R., et al. Fish consumption shifts lipoprotein subfractions to a less atherogenic pattern in humans. J Nutr 2004, 134:1724-1728.
23. Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5:S9-S17.
24. Jarauta E., Mateo-Gallego R., Gilabert R., Plana N., Junyent M., de Groot E., et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis 2012, 22:591-597.
25. Balestrieri G.P., Maffi V., Sleiman I., Spandrio S., Di Stefano O., Salvi A., et al. Fish oil supplementation in patients with heterozygous familial hypercholesterolemia. Recenti Prog Med 1996, 87:102-105.
26. Engler M.M., Engler M.B., Malloy M., Chiu E., Besio D., Paul S., et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther 2004, 42:672-679.
27. Chan D.C., Watts G.F. Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism 2012, 61:3-11.
28. de Sauvage Nolting P.R., Defesche J.C., Buirma R.J., Hutten B.A., Lansberg P.J., Kastelein J.J. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003, 253:161-168.
29. Neil H.A., Seagroatt V., Betteridge D.J., Cooper M.P., Durrington P.N., Miller J.P., et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 2004, 90:1431-1437.
30. Harris W.S. The omega-3 index: from biomarker to risk marker to risk factor. Curr Atheroscler Rep 2009, 11:411-417.
31. Welch A.A., Lund E., Amiano P., Dorronsoro M., Brustad M., Kumle M., et al. Variability of fish consumption within the 10 European countries participating in the European Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2002, 5(6B):1273-1285.
32. Gómez-Gerique J.A., Gutiérrez-Fuentes J.A., Montoya M.T., Porres A., Rueda A., Avellaneda A., et al. Lipid profile of the Spanish population: the DRECE [diet and risk of cardiovascular disease in Spain] study. DRECE study group. Med Clin. [Barc] 1999, 113:730-735.
33. Sala-Vila A., Cofán M., Pérez-Heras A., Núñez I., Gilabert R., Junyent M., et al. Fatty acids in serum phospholipids and carotid intima-media thickness in Spanish subjects with primary dyslipidemia. Am J Clin Nutr 2010, 92:186-193.
34. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847e70.
35. Attie A.D., Krauss R.M., Gray-Keller M.P., Brownlie A., Miyazaki M., Kastelein J.J., et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 2002, 43:1899-1907.
36. Chong M.F.F., Hodson L., Bickerton A.S., Roberts R., Neville M., Karpe F., et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr 2008, 87:817-823.
37. Wei M.Y., Jacobson T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011, 13:474-483.
38. Jacobson T.A., Glickstein S.B., Rowe J.D., Soni P.N. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012, 6:5-18.
39. Caslake M.J., Miles E.A., Kofler B.M., Lietz G., Curtis P., Armah C.K., et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 2008, 88:618-629.
40. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006, 63:1545-1550.
41. Hodson L., Skeaff C.M., Fielding B.A. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Progr Lipid Res. 2008, 47:348-380.
42. Saadatian-Elahi M., Slimani N., Chajès V., Jenab M., Goudable J., Biessy C., et al. Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2009, 89:331-346.
43. Garcia-Closas R., Berenguer A., González C.A. Changes in food supply in Mediterranean countries from 1961 to 2001. Public Health Nutr 2006, 9:53-60.
44. Kris-Etherton P.M., Harris W.S., Appel L.J., American Heart Association, Nutrition Committee Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
45. Burillo E., Martin-Fuentes P., Mateo-Gallego R., Baila-Rueda L., Cenarro A., Ros E., et al. Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?. Curr Vasc Pharmacol 2012, 10:432-441.
46. Ip S., Lichtenstein A.H., Chung M., Lau J., Balk E.M. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009, 150:474-484.
47. Lindqvist H.M., Langkilde A.M., Undeland I., Sandberg A.S. Herring (Clupea harengus) intake influences lipoproteins but not inflammatory and oxidation markers in overweight men. Br J Nutr 2009, 101:383-390.
48. Rosenson R.S., Brewer H.B., Chapman M.J., Fazio S., Hussain M.M., Kontush A., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
49. Guerin M. Reverse cholesterol transport in familial hypercholesterolemia. Curr Opin Lipidol 2012, 23:377-385.